News
ALDX
4.880
+0.41%
0.020
Analysts’ Top Healthcare Picks: Aldeyra Therapeutics (ALDX), Keros Therapeutics (KROS)
TipRanks · 5d ago
Weekly Report: what happened at ALDX last week (1209-1213)?
Weekly Report · 5d ago
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?
NASDAQ · 12/09 15:05
Positive Outlook for Aldeyra Therapeutics: Buy Rating Backed by Promising Reproxalap Prospects and Strategic Partnership with AbbVie
TipRanks · 12/09 11:32
Weekly Report: what happened at ALDX last week (1202-1206)?
Weekly Report · 12/09 09:45
Oppenheimer pharmaceuticals analysts hold analyst/industry conference call
TipRanks · 12/03 22:25
Weekly Report: what happened at ALDX last week (1125-1129)?
Weekly Report · 12/02 09:46
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
Barchart · 12/02 06:00
Weekly Report: what happened at ALDX last week (1118-1122)?
Weekly Report · 11/25 09:43
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
NASDAQ · 11/19 15:00
Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application
Dow Jones · 11/18 20:05
Aldeyra announces FDA acceptance of resubmitted reproxalap application
Seeking Alpha · 11/18 17:09
Aldeyra Therapeutics Says FDA Accepts NDA For Reproxalap In Dry Eye Disease
NASDAQ · 11/18 12:34
Market-Moving News for November 18th
Benzinga · 11/18 12:27
Aldeyra says FDA accepts reproxalap NDA, AbbVie deal expanded to $100M
TipRanks · 11/18 12:16
ALDEYRA THERAPEUTICS INC - PDUFA DATE SET FOR APRIL 2, 2025
Reuters · 11/18 12:00
ALDEYRA THERAPEUTICS INC: ABBVIE HAS ALSO INDEPENDENTLY INITIATED CERTAIN PRE-COMMERCIAL PLANNING ACTIVITIES
Reuters · 11/18 12:00
Weekly Report: what happened at ALDX last week (1111-1115)?
Weekly Report · 11/18 09:42
More
Webull provides a variety of real-time ALDX stock news. You can receive the latest news about Aldeyra Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.